Welcome to our dedicated page for PMGC Holdings news (Ticker: ELAB), a resource for investors and traders seeking the latest updates and insights on PMGC Holdings stock.
PMGC Holdings Inc. reports news across a holding-company portfolio that includes precision manufacturing, aerospace and defense supply-chain operations, industrial packaging, defense technology, and bioscience subsidiaries. Recurring company updates cover subsidiary long-term supply agreements, ITAR and aerospace quality standards, customer relationships, manufacturing capacity, and capital actions tied to acquisition-led platform development.
PMGC news also covers NorthStrive Biosciences patent filings and manufacturing work for engineered probiotic assets such as EL-22 and EL-32, as well as Pacific Sun Packaging activity in electronics and IT hardware packaging markets. Defense technology announcements describe subsidiary initiatives involving autonomous systems, counter-drone applications, and GPS-denied navigation environments.
PMGC (NASDAQ: PMGC) announced that its wholly owned subsidiary SVM Machining completed ITAR registration on March 24, 2026 and is in compliance with U.S. export‑control rules.
The company said the registration enables SVM to pursue defense and aerospace programs, increases eligibility as a qualified supplier to Tier 1 defense contractors and supports PMGC's strategy to expand into high‑value, defense‑related manufacturing.
PMGC Holdings (Nasdaq: ELAB) subsidiary NorthStrive Biosciences initiated a preclinical study of EL-32 to evaluate preservation of lean muscle while promoting fat loss, alone and combined with GLP-1 therapy semaglutide. The DIO mouse study will assess body weight, fat mass, lean mass, glycemic markers, and composition, with dosing, analysis, and CRO reporting planned over the coming months to inform potential follow-on studies.
PMGC Holdings (NASDAQ: ELAB) will effect a 1-for-6 reverse stock split of its common stock, effective 12:00 AM ET on March 10, 2026. Each six shares will consolidate into one, fractional holders will receive whole shares, and the CUSIP will change to 73017P508.
The company expects ~3,248,764 shares outstanding before the Split and ~541,461 shares outstanding immediately after, with outstanding awards, options and warrants adjusted proportionally.
NorthStrive Biosciences (Nasdaq: ELAB) filed ten U.S. patent applications on Feb. 19, 2026, extending its EL-22 and EL-32 technologies into animal health and agricultural markets.
The filings cover muscle growth and yield in livestock and poultry, aquaculture growth and emissions reduction, and list ten U.S. application numbers for EL-22 and EL-32.
NorthStrive Biosciences (NASDAQ: ELAB) executed a definitive, exclusive license agreement with Modulant Biosciences for its EL-22 and EL-32 myostatin-engineered probiotic programs for non-human animal health (worldwide excluding the Republic of Korea).
The License grants Modulant exclusive, royalty-bearing, sublicensable rights to develop, manufacture, and commercialize products from issued patents, pending applications, and know-how; Modulant assumes development, regulatory, manufacturing, and commercialization responsibilities while the agreement excludes any human pharmaceutical applications.
NorthStrive Biosciences (NASDAQ:ELAB) updated the Phase III timeline for its AI development program with strategic partner Yuva Biosciences. Phase III was initiated on December 17, 2025 and initially expected to last ~6–9 weeks. Upgraded sixth‑generation classifier models improve screening accuracy, and Yuva now expects Phase III results in Q2 2026. NorthStrive notes it does not control Yuva’s timeline and results remain subject to change.
PMGC Holdings (NASDAQ: ELAB) completed the acquisition of SVM Machining, a Northern California ISO 9001:2015 certified CNC precision machining firm. PMGC purchased 100% of SVM on a cash-free, debt-free basis for a $2.25M base price with a $250,000 indemnification holdback and earnout potential. SVM reported $3,042,701 revenue for the fiscal year ended December 31, 2024. The deal expands PMGC’s multi-site precision manufacturing platform across aerospace, defense, medical, semiconductor, biotech, and transportation markets.
PMGC Holdings (NASDAQ: ELAB) announced that its investment arm PMGC Capital acquired a non-controlling equity stake in Nuclea Energy, a company developing Micro Modular Reactors (MMR). The transaction closed on November 6, 2025.
The move aligns with PMGC Capital's focus on next-generation energy infrastructure, energy security, and decarbonization. The release cites a projected global SMR/MMR market growth from about $7.5 billion in 2025 to more than $16 billion by 2034, a ~9% CAGR, and notes demand drivers including grid stability, industrial loads, and data centers.
PMGC Holdings (NASDAQ: ELAB) will effect a 1-for-4 reverse stock split of its common stock effective Jan 6, 2026 at 9:00 AM ET. Every four issued or authorized shares will be consolidated into one share, with fractional-share holders receiving one full share for each fractional portion.
The trading symbol remains ELAB and the new CUSIP is 73017P409. Outstanding equity awards, options, reserved shares, and warrants and their exercise prices will be proportionally adjusted. Immediately prior to the split the company had approximately 2,014,852 issued and outstanding shares; following the split it expects about 503,713 shares outstanding, subject to customary rounding and adjustments. Certificate holders can exchange through VStock Transfer.
PMGC Holdings (NASDAQ: ELAB) will effect a 1-for-4 reverse stock split of its common stock at 9:00 AM ET on January 6, 2026. Every four issued or authorized shares will be consolidated into one share and fractional entitlements will be converted into whole shares.
The trading symbol will remain ELAB and the company will use a new CUSIP 73017P409. Outstanding awards, options, reserved shares, and warrant shares and exercise prices will be adjusted proportionally. Transfer agent VStock Transfer will handle certificate exchanges.
The company expects approximately 2,034,882 shares outstanding immediately prior to the split and about 508,721 shares outstanding immediately following the split.